Related references
Note: Only part of the references are listed.Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers
Hiroki Sato et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
Mauricio Fernando Silva Almeida Ribeiro et al.
NPJ PRECISION ONCOLOGY (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Jang Ho Cho et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies
Xiang Zhai et al.
BIOCHEMISTRY (2020)
Mechanisms of resistance to osimertinib
Chiara Lazzari et al.
JOURNAL OF THORACIC DISEASE (2020)
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
Jiyun Lee et al.
CANCER RESEARCH AND TREATMENT (2019)
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Wenxian Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
Sha Zhao et al.
LUNG CANCER (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Zuan-Fu Lim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Sun Min Lim et al.
CANCER TREATMENT REVIEWS (2018)
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
V A Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2018)
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Tatsuya Nagano et al.
CELLS (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma
Hestia Mellert et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
Judith N. Mueller et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
Zhen Wang et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
Masato Chiba et al.
BMC CANCER (2017)
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Shuhang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
A Novel EGFRC797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay
Roopika Menon et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine
J. M. Heuckmann et al.
ANNALS OF ONCOLOGY (2015)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Dalia Ercan et al.
CLINICAL CANCER RESEARCH (2015)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
Chao-Hua Chiu et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors
Satsuki Matsushima et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Sensitive Detection of KRAS Mutations Using Enhanced-ice-COLD-PCR Mutation Enrichment and Direct Sequence Identification
Alexandre How Kit et al.
HUMAN MUTATION (2013)
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
Nadine Demierre et al.
LUNG CANCER (2013)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Share Paper
